WHO backs wider use of weight-loss medicines, calling obesity a chronic disease
The guidance focuses on GLP-1 therapies – medicines such as liraglutide, semaglutide and tirzepatide – and offers conditional recommendations on how they can be used safely as part of long-term treatment. Living with obesity More than one billion people worldwide live with obesity, which was linked to 3.7 million deaths in 2024. Without stronger action, […]
Continue Reading